By using our website, you are agreeing to cookies being stored and Google Analytics being used on your device in order to offer the best possible service. You can find more information on thishere.
Austria.
Bridge to New Markets.

Pfizer invests EUR 54 million in Austrian-based research

Pfizer building in Viennna © Pfizer

New medicines are being developed in cooperation with local medical universities, research institutions and hospitals. Clinical research carried out by Pfizer focuses on new treatments for cancer, chronic-inflammatory diseases, cardiovascular diseases, rare diseases, pain and new vaccines. In 2017 Pfizer also invested EUR 54 million in Austria.

One example of the company’s cooperation in the field of clinical research is its partnership with the academic institution ABCSG. The study group led by Prof. Michael Gnant (Medical University of Vienna) heads a registration trial with a substance developed by Pfizer to treat breast cancer. The study is completely financed by Pfizer and ABCSG is in charge of data, patient and project management in 21 countries across the globe. 5,600 patients are to take part in the study over a period of fifteen years. 18 hospitals and about 500 patients are involved just in Austria. „The fact that responsibility for a globally implemented Phase III study is in Austrian hands is a nice acknowledgement of the longstanding work done by ABCSG”, explains Prof. Gnant, President of ABCSG.

Share on Facebook Share on Facebook Share on Twitter Share on Twitter Share on Linkedin Share on Linkedin

Testimonials

Events

Meet us at events, seminars and trade shows - worldwide.

  • ABA's Open Day 2021: Austria - Your ICT and Innovation Hub in the Heart of Europe

    11 March 2021/ 09.00am + 05.00 pm, Online Conference

  • Meet us @ International Machinery Forum 2021 - The Factory of Tomorrow

    11.03 - 12.03 2021, Online Conference

Austria Map

Find the perfect location for your company

Austria stands out due to its long-term reliable and stable conditions. These features are particularly important for a research-based company such as Boehringer Ingelheim. Furthermore, Vienna is a city with a good research infrastructure and a high quality of life, and is thus also an interesting place for highly qualified employees from Austria and abroad.

Boehringer Ingelheim

Logo
More testimonials

news from the business location Austria

OMV and Kommunalkredit invest in the production of green hydrogen

The Austrian oil and gas company OMV and Kommunalkredit Austria AG (Kommunalkredit) have announced a joint investment in the construction of Austria’s largest electrolysis plant to be located in the OMV Schwechat Refinery.

Evotec SE

Evotec is an active substance research company which rapidly presses ahead with innovative product approaches on the basis of development partnerships with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists.

More news All blog posts